Ad Scientiam develops innovative digital solutions for patient monitoring in real life. Building on the growing possibilities offered by smartphones, Ad Scientiam creates new clinically-validated medical standards, in a collaborative ecosystem of patients, doctors and researchers.

MSCopilot® is Ad Scientiam’s first solution CE marked as a Class 1 medical device, dedicated to the monitoring of patients with multiple sclerosis. Ad Scientiam works on several other solutions in Alzheimer’s Disease, Parkinson's Disease, Rheumatoid Arthritis, etc.

Ad Scientiam employs 25 people at its two sites in France (the Pitié-Salpêtrière hospital and Station F campus) and in the United States (Seattle).